Were you diagnosed with NAION after taking Ozempic, Wegovy, or Rybelsus?

Patients who have taken GLP-1 medications such as Ozempic, Wegovy, or Rybelsus and subsequently experienced sudden vision loss may be suffering from a serious eye condition called non-arteritic anterior ischemic optic neuropathy (NAION).

NAION develops when the optic nerve does not receive enough blood flow, potentially causing sudden, irreversible vision loss. Recent medical studies have identified a possible connection between semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, and an increased risk of NAION.

For individuals in Gulfport and across the Mississippi Gulf Coast who have received a NAION diagnosis after taking one of these medications, legal action may be an option.

Can You File a GLP-1 NAION Lawsuit in Mississippi?

Patients across the country have filed lawsuits alleging that semuglutide medications contributed to the development of NAION and resulting vision damage. Federal GLP-1 NAION cases have been consolidated into multidistrict litigation (MDL No. 3163) in the U.S. District Court for the Eastern District of Pennsylvania.

Mississippi residents who experienced vision loss after using Ozempic, Wegovy, or Rybelsus may also be eligible to pursue compensation, depending on their individual circumstances.

If you or a loved one has been diagnosed with NAION after taking a GLP-1 medication, the Gulfport attorneys at Morris Bart can evaluate your situation and explain your potential legal options.

For a free legal consultation with a lawyer serving Gulfport, call 800-537-8185

What Are GLP-1 Medications?

GLP-1 receptor agonists are prescription medications commonly used to treat conditions including type 2 diabetes and, in certain formulations, obesity. They work by imitating a hormone that helps regulate blood sugar levels, appetite, and digestion.

Semaglutide is the active ingredient in several widely used GLP-1 medications, including:

Ozempic: Primarily prescribed to manage type 2 diabetes.
Wegovy: Approved for chronic weight management and certain other indications.
Rybelsus: An oral semaglutide medication used to treat type 2 diabetes.

Although these medications have demonstrated clinical benefits, questions have emerged about their potential relationship to certain serious eye conditions.

In 2025, European regulators determined that NAION should be recognized as a very rare side effect of semaglutide and recommended corresponding updates to product information.

What Is NAION and How Does It Affect Vision?

Non-arteritic anterior ischemic optic neuropathy (NAION) occurs when blood flow to the optic nerve becomes insufficient, damaging the nerve responsible for transmitting visual information from the eye to the brain.

Unlike many eye conditions that progress gradually, NAION often develops suddenly and without pain. Some patients first recognize symptoms upon waking up, noticing that their vision has become blurry, darkened, or partially obstructed.

NAION generally affects one eye initially, although the other eye can also be affected. Because damage to the optic nerve may be permanent, recognizing symptoms and obtaining medical attention quickly is important.

Click to contact our Gulfport Dangerous Drug Attorney today

What Are the Warning Signs of NAION?

Common symptoms of NAION include:

Sudden, painless loss of vision, typically in one eye
Blurred, dimmed, or reduced eyesight
Partial loss of peripheral or central vision
Dark or missing areas within the field of vision
Difficulty seeing objects in the upper or lower visual field
Changes in color perception or contrast sensitivity

Not everyone who experiences these symptoms has NAION, and vision changes can have several possible causes.

Anyone experiencing sudden or significant vision loss should seek immediate medical evaluation, regardless of whether they are taking a GLP-1 medication.

Is There a Connection Between Semaglutide and NAION?

Researchers have examined whether semaglutide use is associated with a greater likelihood of developing NAION. Multiple observational studies have reported an association, although questions remain about the precise relationship and the role of other underlying health conditions.

In 2025, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee concluded that NAION is a very rare side effect of semaglutide-containing medications. Its review estimated approximately one additional NAION case per 10,000 person-years of treatment.

Despite these findings, the manufacturers have contested allegations that their medications caused patients’ injuries. Ongoing litigation seeks to address whether the medications contributed to individual cases of NAION and whether patients received adequate warnings about potential risks.

Who May Qualify for a GLP-1 NAION Lawsuit?

Not every person who has taken a GLP-1 medication or experienced vision changes will qualify for a lawsuit. Eligibility depends on several factors, including medical documentation, prescription history, and the circumstances surrounding the diagnosis.

When reviewing a potential GLP-1 NAION claim, an attorney may consider:

Medication history: Whether the individual used Ozempic, Wegovy, Rybelsus, or another relevant medication.
Duration of use: When treatment began and how long the medication was taken.
NAION diagnosis: Whether an ophthalmologist or other qualified medical professional confirmed the condition.
Timing of symptoms: When vision changes developed in relation to medication use.
Medical evidence: Prescription records, eye examinations, diagnostic testing, and treatment documentation.
Extent of injury: The severity of vision loss and its effects on daily life.
Other risk factors: Whether underlying health conditions may have contributed to the diagnosis.

A confirmed NAION diagnosis following semaglutide use does not automatically establish that the medication caused the injury. However, it may warrant a legal review.

The Gulfport legal team at Morris Bart can help Mississippi residents understand whether their circumstances may support a potential claim.

What If I Took Ozempic but Haven’t Been Diagnosed With NAION?

Most patients who use semaglutide medications do not develop NAION. Although research has identified a potential risk, the condition remains very rare.

If you currently take Ozempic, Wegovy, or Rybelsus and have concerns about your vision, speak with your prescribing healthcare provider. Do not discontinue a prescribed medication without medical guidance.

If you notice sudden vision loss or other significant visual disturbances, seek immediate medical attention. A qualified eye specialist can evaluate your symptoms and determine whether NAION or another condition may be responsible.

How Can a Gulfport GLP-1 NAION Lawyer Help?

Pursuing a claim involving a prescription medication can be complicated, particularly when medical research, product warnings, and federal litigation are involved.

An attorney can help determine whether the facts of your case support pursuing legal action. This may involve reviewing prescription records, examining medical documentation, identifying potentially responsible parties, and evaluating the impact of your vision loss.

Morris Bart serves clients in Gulfport and throughout the Mississippi Gulf Coast, including Biloxi, Long Beach, and surrounding communities. Our team can review your potential GLP-1 NAION claim and discuss the legal options that may be available.

Speak With a Gulfport GLP-1 NAION Attorney Today

A NAION diagnosis can bring unexpected challenges, particularly when vision loss affects your independence, ability to work, and everyday activities. If you or a loved one developed NAION after taking Ozempic, Wegovy, Rybelsus, or another GLP-1 medication, you may have grounds to pursue legal action.

The attorneys at Morris Bart are available to review your circumstances, answer your questions, and help you understand your next steps. Call today for a free consultation. One Call, That’s All.

Questions?Call 800-537-8185
to find a Morris Bart office near you.